Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer

Clinical Cancer Research

Volumn 23, Issue 2, 2017, Pages 363-369

  Saylor, Philip J ^a,b   Lee, Richard J ^a,b   Arora, Kshitij S ^a,b   Deshpande, Vikram ^a,b   Hu, Rong ^a,b   Olivier, Kara ^a   Meneely, Erika ^a   Rivera, Miguel N ^a,b   Ting, David T ^a,b   Wu, Chin Lee ^a,b   Miyamoto, David T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BICALUTAMIDE; BRANCHED CHAIN RNA; ENZALUTAMIDE; MESSENGER RNA; RNA; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; ISOPROTEIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; METASTATIC CASTRATION SENSITIVE PROSTATE CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RNA SPLICING; SURVIVAL PREDICTION; ADENOCARCINOMA; CANCER GRADING; CASTRATION RESISTANT PROSTATE CANCER; DISEASE FREE SURVIVAL; GENETICS; PATHOLOGY; PROGNOSIS; RNA PROBE; TUMOR CELL LINE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; IN SITU HYBRIDIZATION; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RNA PROBES; RNA SPLICING;

EID: 85010972345     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0237     Document Type: Article

References (20)

1. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006;98:973-8.
2. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
3. Hall M, Schultheiss T, Farino G, Wong J. Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF). J Clin Oncol 2015;33 (suppl 7, abstr 143).
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
6. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71:6019-29.
7. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002.
8. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
9. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 2015;67:53-60.
10. Thadani-Mulero M, Portella L, Sun S, Matov A, Vessella RL, Corey E, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014;74:2270-82.
11. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA oncology 2015;1:582-91.
12. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
14. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
15. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PloS One 2011;6:e19059.
16. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
17. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015;163:1011-25.
18. Ferrone CR, Ting DT, Shahid M, Konstantinidis I, Sabbatino T, Goyal F, et al. The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology. Ann Surg Oncol 2016;23:290-6.
19. Shahid M, Mubeen A, Tse J, Kakar S, Bateman AC, Borger D, et al. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol 2015;39:25-34.
20. Kerr DA, Arora KS, Mahadevan KK, Hornick JL, Krane JF, Rivera MN, et al. Performance of a branch chain RNA in situ hybridization assay for the detection of high-risk human papillomavirus in head and neck squamous cell carcinoma. Am J Surg Pathol 2015;39:1643-52.